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Background: Paraoxonase-1 (PON1) is an enzyme with numerous functions and receives an increasing interest in
clinical and epidemiological studies. Sometimes samples are stored for longer periods at a certain temperature.
Therefore the stability of PON1 activity must be checked and retained upon storage for longer periods.
Results: In this study the stability of PON1 activity has been tested in human serum samples during storage up to
12 months at 3 commonly used temperatures, -20°C, -70°C and −196°C. It was found that the stability of the PON1
activity is constant during 12 months of storage at −70°C and −196°C. Storage at −20°C resulted in a small but
statistically significant decrease after 6 months to about 94% of its original value. Nonetheless, the rank order
between the samples at T = 0 and 12 months remained the same. The same temperature dependence was found
for the associated high-density lipoprotein.
Conclusions: It can be concluded that −70°C is the right temperature for storage to maintain the PON1 activity for
at least one year. Storage at a lower temperature in liquid nitrogen (−196°C) is not necessary.
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In medical and epidemiological research the stability and
activity of biomarkers is very important especially when
they are stored for a long period of time at a certain
temperature. Also standardization of processes such as
blood withdrawal, centrifugation and time until storage
at low temperatures is necessary. Other important para-
meters include the time delay until storage, the storage
temperature and the storage time until analysis all con-
tribute to the process of gathering a reliable set of data
for statistical analysis.
Paraoxonase-1 (PON1) has obtained during the last
years much interest in clinical and epidemiological re-
search focusing on its protective role in vascular disease
[1,2] diabetes [3-5] and end-stage renal disease [6]. PON1
is a high-density lipoprotein (HDL)-associated enzyme
exhibiting anti-atherogenic properties and protects low-
density lipoprotein (LDL) against oxidation in the preven-
tion of atherosclerosis. Besides these protecting properties,
PON1 exhibits a range of important activities, including* Correspondence: eugene.jansen@rivm.nl
1Laboratory for Health Protection Research, National Institute of Public Health
and the Environment, PO Box 1, Bilthoven, BA 3720, The Netherlands
Full list of author information is available at the end of the article
© 2012 Beekhof et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordrug metabolism, detoxification of organophosphates such
as nerve agents and also plays a protective role as homo-
cystein thiolactonase activity against oxidative damage of
lipoproteins such as homocysteinylation [3,6] and interfer-
ence with lipid metabolism [7-10].
In the present study the stability of PON1 activity and
HDL-C (HDL-cholesterol) concentration in serum sam-
ples have been tested after a storage time up to 12 months
at 3 different commonly used temperatures.
Results
The initial concentrations of PON1 at t = 0 have been deter-
mined within 4 hours after centrifugation. Mean±SD for
PON1 for the 16 volunteers was 67.7± 16.3 U/L with a
range of 43.1-109.7 U/L with a median value of 67.4 U/L.
The time and temperature dependence of PON1 activity
which was corrected with the values of the quality control
sample is shown in Figure 1.
Upon storage at −20°C, there was a statistically significant
decrease in PON1 activity after 6 and 12 months to 96%
and 94% compared with the activity of PON1 in the sam-
ples stored at −70°C or −196°C (p< 0.01 and p<0.001, re-
spectively). The differences between values at −70°C and at
−196°C were not statistically significant. The rank order ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and


















Figure 1 Long-time stability of PON1 activity upon storage at
different temperatures, corrected for the levels of the control
sample.
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storage at −20°C, however remained unchanged with a
good correlation (R2) of 0.954 with the data at T=0. Stor-
age at −70°C or −196°C showed no decrease in the mean
value of PON1 activity at all time points. The correlation
coefficients with the data at T=0 were 0.973 and 0.969 for
the samples stored at −70°C and −196°C, respectively.
To investigate the influence of storage on the binding of
PON1 to high-density lipoprotein (HDL), the parameter
HDL-cholesterol (HDL-C) was also measured. Figure 2
shows the stability of the HDL-C concentration corrected
for the control sample. A similar pattern was observed as
for the PON1 activity. Storage at −70°C and −196°C did
not affect the HDL-C concentration, but storage at −20°C
decreased the HDL-C concentration to 92% of the original
value after 6 and 12 months. At these time points there
was a statistically significant difference between the mean
values of the samples stored at −20°C and at −196°C
(p<0.001). No statistical differences were observed between


















Figure 2 Long-time stability of HDL-cholesterol upon storage
at different temperatures, corrected for the levels of the
control sample.Discussion
This study shows that the stability of PON1 activity is good
upon long time storage up to 12 months. At time points 1,
9 and 12 months there seems to be a small decrease in the
PON1 activity relative to T=0 but after correction for the
control serum data, the PON1 activity of all time points at
storage temperatures of −70°C and −196°C did not deviate
from the value at T=0. Only at time points of 9 and
12 months, the activity of the samples stored at−20°C
showed a statistically significant decrease in activity to 94%
compared with the activities of the samples stored at −70°C
and −196°C. Because the rank order compared with sam-
ples at T=0 was very good, the PON1 activity data of sam-
ples stored at −20°C for 12 months still can be used in
epidemiological research for statistical analysis.
Similar effects were observed with HDL-C after correc-
tion for the control serum data, where the HDL-C con-
centration after 6 and 12 months stored at −20°C showed
a decrease in activity to about 92% compared with the ac-
tivities of the samples stored at −70°C and −196°C.
Whether this decrease in both PON1 activity and HDL-C
concentration are correlated can not be determined with
the present data.
The present study confirms the findings of Huen et al.
[11] who also found a good stability of the PON1 activity
up to 2 years at −80°C. In addition, two other temperatures
(−20°C and −196°C) have been tested in this study.
Conclusions
In conclusion, the PON1 activity in serum samples stored
at −70°C or −196°C are perfectly stable during one year of
storage. Upon storage at −20°C a small decrease to 96%
and 94% has been observed after 6 months of storage. The
same temperature dependence was observed for HDL-C.
Because there were no differences found in stability of
PON1 stored at −70°C and −196°C, complicated and ex-
pensive storage devices such as a container with liquid ni-
trogen for a storage temperature of −196°C are not
necessary to maintain the activity of PON1.
Methods
For the stability study, serum samples of 16 healthy human
volunteers, 8 men and 8 women (blood donors) were used.
The mean age was 43.8 years and the health status was
checked with the procedures used in the Blood Bank. Sam-
ples were obtained from the Central Blood Laboratory of
the Red Cross in Amsterdam with written permission of
the volunteers. After blood withdrawal, serum samples
were prepared within two hours, divided in aliquots and
stored at different temperatures.
The initial activity of PON1 and the HDL-C concentra-
tion at t = 0 were determined within 4 hours after centrifu-
gation. For long-term stability samples have been stored for

















Figure 3 Levels of PON1 activity (single measurements) in the
control sample during the course of the experiment.
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check. Measurements of PON1 activity and HDL-C con-
centration were performed at day 4 and 14 and after 1, 2, 6
and 12 months. Samples stored at −70°C were kept in a
refrigerator equipped with temperature recorder and sound
alarm. Measurements of PON1 activity and HDL-C con-
centration were performed at day 14 and after 2, 6 and
12 months. Samples stored at −196°C were kept in a con-
tainer with liquid nitrogen equipped with an automatic fill-
ing device and sound alarm. Measurements of PON1
activity and HDL-C concentration were performed after 1,
2, 6 and 12 months.
At all time points the statistical difference (95% confi-
dence interval) of the values from the initial value at
t = 0 were determined with a t-test for two-samples as-
suming equal variances.
PON1 activity was determined in serum on an auto
analyzer (Hitachi 912, Roche Diagnostics) as described
by Himbergen et al. [12]. Shortly, paraoxon was used as
substrate for PON-1 in the presence of 2.3 M NaCl and
2.3 mM CaCl2. in Tris/HCl buffer at pH 8.5. The forma-
tion of p-nitrophenol was followed kinetically at
450 nm with 546 nm as reference wavelength.
Precinorm-U has been used as a control serum. HDL-C
concentrations in serum have been determined on an
auto analyzer (Hitachi 912, Roche Diagnostics) with
dedicated kits. The values of the control serum for
PON1 activity during the course of the experiment are
shown in Figure 3.
The measurements were performed as a single meas-
urement, except on day 0 (duplicate measurements). For
each measurement a new aliquot was taken. In the
Figures, the PON1 activity and the HDL-C concentra-
tion have been expressed as percentage relative to the
value obtained in fresh serum immediately after blood
withdrawal (time point T= 0).
Competing interests
None of the authors has any financial or non-financial competing interests.Authors’ contributions
PKB has made substantial contribution to the conception, acquisition of the
data, analysis and interpretation of the data. MG has made important critical
and intellectual contribution to the paper. EHJMJ has made a major
contribution to the interpretation of the data and drafting and writing of the
paper. All authors read and approved the final manuscript.
Acknowledgements
The authors are indebted to Erna Schenk who contributed to the
organization of the study.
Author details
1Laboratory for Health Protection Research, National Institute of Public Health
and the Environment, PO Box 1, Bilthoven, BA 3720, The Netherlands.
2Department of Endocrinology, Kharkiv Postgraduate Medical Academy,
Korchagintsiv Str., 58, Kharkiv 61176, Ukraine.
Received: 16 January 2012 Accepted: 4 May 2012
Published: 14 May 2012
References
1. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP,
Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian
CP: Human PON1, a biomarker of risk of disease and exposure. Chem Biol
Interact 2010, 187:355–361.
2. Tavori H, Rosenblat M, Vaya J, Aviram M: Paraoxonase 1 interactions with
atherosclerotic lesions and arterial macrophages protect against foam
cell formation and atherosclerosis development. Clinical Lipidology 2010,
5:685–697.
3. Camuzcuoglu H, Toy H, Cakir H, Celik H, Erel O: Decreased paraoxonase
and arylesterase activities in the pathogenesis of future atherosclerotic
heart disease in women with gestational diabetes mellitus. J Womens
Health 2009, 18:1435–1439.
4. Gorshunskaya M, Karachentsev Y, Atramentova L, Tyzhnenko T, Kravchun N,
Pochernyaev A, Poltorak V: Q192R polymorphism of PON-1 gene in type 2
diabetes patients. Cytol Genet 2011, 45:38–40.
5. van den Berg SW, Jansen EHJM, Kruijshoop M, Beekhof PK, Blaak E, van der
Kallen CJ, van Greevenbroek MMJ, Feskens EJM: Paraoxonase 1–192
phenotype and lower paraoxonase 1 activity are associated with
increased risk of Type 2 diabetes (the CODAM Study). Diabet Med 2008,
25:186–193.
6. Gugliucci A, Kinugasa E, Kotani K, Caccavello R, Kimura S: Serum
paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal
disease patients than in healthy control subjects and increases after
hemodialysis. Clin Chem Lab Med 2011, 49:61–67.
7. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS: The 192R/Q polymorphs of
serum paraoxonase PON1 differ in HDL binding, lipolactonase
stimulation and cholesterol efflux. J Lipid Res 2006, 47:2492–2502.
8. Loued S, Isabelle M, Berrougui H, Khalil A: The anti-inflammatory effect of
paraoxonase 1 against oxidized lipids depends on its association with
high density lipoproteins. Life Sci 2012, 90:82–88.
9. Mackness M, Mackness B: Effect of dilution on high-density
lipoprotein associated paraoxonase-1 activity. Clin Biochem 2011,
44:1270–1271.
10. Zafiropoulos A, Linardakis M, Jansen EHJM, Tsatsakis AM, Kafatos A,
Tzanakakis GN: Paraoxonase 1 R/Q alleles are associated with differential
accumulation of saturated versus 20:5n3 fatty acid in human adipose
tissue. J Lipid Res 2010, 51:1991–2000.
11. Huen K, Richter R, Furlong C, Eskenazi B, Holland N: Validation of
PON1 enzyme activity assays for longitudinal studies. Clin Chim
Acta 2009, 402:67–74.
12. van Himbergen TM, Roest M, de Graaf J, Jansen EHJM, Hattori H, Kastelein
JJP, Voorbij HAM, Stalenhoef AFH, van Tits LJH: Indications that
paraoxonase-1 contributes to plasma high-density lipoprotein levels in
familial hypercholesterolemia. J Lipid Res 2005, 46:445–451.
doi:10.1186/1476-511X-11-53
Cite this article as: Beekhof et al.: Long term stability of paraoxonase-1
and high-density lipoprotein in human serum. Lipids in Health and
Disease 2012 11:53.
